vs
NELNET INC（NNI）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
RECURSION PHARMACEUTICALS, INC.的季度营收约是NELNET INC的1.1倍（$35.5M vs $33.5M），NELNET INC净利率更高（172.3% vs -304.2%，领先476.5%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs 79.6%），NELNET INC自由现金流更多（$396.7M vs $-47.3M），过去两年NELNET INC的营收复合增速更高（62.0% vs 60.5%）
Nelnet（耐尔奈特）是总部位于美国内布拉斯加州林肯市的综合性企业集团，核心业务涵盖金融服务领域，主营学生贷款、消费贷款的发放与服务，同时设有投资板块与互联网银行，还持有有线电视及网络服务商Allo Fiber 26%的股权。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
NNI vs RXRX — 直观对比
营收规模更大
RXRX
是对方的1.1倍
$33.5M
营收增速更快
RXRX
高出602.1%
79.6%
净利率更高
NNI
高出476.5%
-304.2%
自由现金流更多
NNI
多$444.1M
$-47.3M
两年增速更快
NNI
近两年复合增速
60.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $33.5M | $35.5M |
| 净利润 | $57.8M | $-108.1M |
| 毛利率 | 50.5% | 59.8% |
| 营业利润率 | — | -304.8% |
| 净利率 | 172.3% | -304.2% |
| 营收同比 | 79.6% | 681.7% |
| 净利润同比 | -8.5% | 39.6% |
| 每股收益（稀释后） | $1.62 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NNIRXRX
| Q4 25 | $33.5M | $35.5M | ||
| Q3 25 | $23.2M | $5.2M | ||
| Q2 25 | $26.1M | $19.2M | ||
| Q1 25 | $24.7M | $14.7M | ||
| Q4 24 | $18.7M | $4.5M | ||
| Q3 24 | $16.6M | $26.1M | ||
| Q2 24 | $14.9M | $14.4M | ||
| Q1 24 | $12.8M | $13.8M |
净利润NNIRXRX
| Q4 25 | $57.8M | $-108.1M | ||
| Q3 25 | $106.7M | $-162.3M | ||
| Q2 25 | $181.5M | $-171.9M | ||
| Q1 25 | $82.6M | $-202.5M | ||
| Q4 24 | $63.2M | $-178.9M | ||
| Q3 24 | $2.4M | $-95.8M | ||
| Q2 24 | $45.1M | $-97.5M | ||
| Q1 24 | $73.4M | $-91.4M |
毛利率NNIRXRX
| Q4 25 | 50.5% | 59.8% | ||
| Q3 25 | 29.6% | -183.8% | ||
| Q2 25 | 29.8% | -4.9% | ||
| Q1 25 | 30.5% | -48.0% | ||
| Q4 24 | 13.7% | -181.4% | ||
| Q3 24 | 0.1% | 53.7% | ||
| Q2 24 | 27.3% | 36.2% | ||
| Q1 24 | 15.3% | 19.1% |
营业利润率NNIRXRX
| Q4 25 | — | -304.8% | ||
| Q3 25 | — | -3327.6% | ||
| Q2 25 | — | -916.8% | ||
| Q1 25 | — | -1297.9% | ||
| Q4 24 | 97.7% | -4042.4% | ||
| Q3 24 | -13.4% | -377.1% | ||
| Q2 24 | 88.0% | -697.4% | ||
| Q1 24 | — | -698.4% |
净利率NNIRXRX
| Q4 25 | 172.3% | -304.2% | ||
| Q3 25 | 460.5% | -3135.3% | ||
| Q2 25 | 694.9% | -894.2% | ||
| Q1 25 | 334.4% | -1373.3% | ||
| Q4 24 | 338.2% | -3935.5% | ||
| Q3 24 | 14.4% | -367.5% | ||
| Q2 24 | 303.6% | -676.6% | ||
| Q1 24 | 574.4% | -662.4% |
每股收益（稀释后）NNIRXRX
| Q4 25 | $1.62 | $-0.17 | ||
| Q3 25 | $2.94 | $-0.36 | ||
| Q2 25 | $4.97 | $-0.41 | ||
| Q1 25 | $2.26 | $-0.50 | ||
| Q4 24 | $1.74 | $-0.56 | ||
| Q3 24 | $0.07 | $-0.34 | ||
| Q2 24 | $1.23 | $-0.40 | ||
| Q1 24 | $1.98 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $296.0M | $743.3M |
| 总债务越低越好 | $7.8B | $9.6M |
| 股东权益账面价值 | $3.7B | $1.1B |
| 总资产 | $14.1B | $1.5B |
| 负债/权益比越低杠杆越低 | 2.11× | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资NNIRXRX
| Q4 25 | $296.0M | $743.3M | ||
| Q3 25 | $216.4M | $659.8M | ||
| Q2 25 | $225.8M | $525.1M | ||
| Q1 25 | $220.5M | $500.5M | ||
| Q4 24 | $194.5M | $594.4M | ||
| Q3 24 | $219.7M | $427.6M | ||
| Q2 24 | $145.5M | $474.3M | ||
| Q1 24 | $179.7M | $296.3M |
总债务NNIRXRX
| Q4 25 | $7.8B | $9.6M | ||
| Q3 25 | $7.8B | $11.9M | ||
| Q2 25 | $7.9B | $14.2M | ||
| Q1 25 | $8.7B | $16.4M | ||
| Q4 24 | $8.3B | $19.0M | ||
| Q3 24 | $8.9B | $20.5M | ||
| Q2 24 | $9.6B | $22.9M | ||
| Q1 24 | $10.6B | — |
股东权益NNIRXRX
| Q4 25 | $3.7B | $1.1B | ||
| Q3 25 | $3.7B | $1.0B | ||
| Q2 25 | $3.6B | $919.1M | ||
| Q1 25 | $3.4B | $933.9M | ||
| Q4 24 | $3.3B | $1.0B | ||
| Q3 24 | $3.3B | $524.6M | ||
| Q2 24 | $3.3B | $584.4M | ||
| Q1 24 | $3.3B | $401.2M |
总资产NNIRXRX
| Q4 25 | $14.1B | $1.5B | ||
| Q3 25 | $13.9B | $1.4B | ||
| Q2 25 | $13.7B | $1.3B | ||
| Q1 25 | $14.2B | $1.3B | ||
| Q4 24 | $13.8B | $1.4B | ||
| Q3 24 | $14.1B | $726.5M | ||
| Q2 24 | $14.5B | $775.9M | ||
| Q1 24 | $15.4B | $557.8M |
负债/权益比NNIRXRX
| Q4 25 | 2.11× | 0.01× | ||
| Q3 25 | 2.14× | 0.01× | ||
| Q2 25 | 2.21× | 0.02× | ||
| Q1 25 | 2.53× | 0.02× | ||
| Q4 24 | 2.48× | 0.02× | ||
| Q3 24 | 2.72× | 0.04× | ||
| Q2 24 | 2.90× | 0.04× | ||
| Q1 24 | 3.20× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $423.0M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | $396.7M | $-47.3M |
| 自由现金流率自由现金流/营收 | 1183.0% | -133.1% |
| 资本支出强度资本支出/营收 | 78.2% | 3.5% |
| 现金转化率经营现金流/净利润 | 7.32× | — |
| 过去12个月自由现金流最近4个季度 | $663.4M | $-378.3M |
8季度趋势，按日历期对齐
经营现金流NNIRXRX
| Q4 25 | $423.0M | $-46.1M | ||
| Q3 25 | $112.4M | $-117.4M | ||
| Q2 25 | $81.8M | $-76.4M | ||
| Q1 25 | $91.2M | $-132.0M | ||
| Q4 24 | $662.9M | $-115.4M | ||
| Q3 24 | $137.0M | $-59.2M | ||
| Q2 24 | $133.8M | $-82.2M | ||
| Q1 24 | $211.6M | $-102.3M |
自由现金流NNIRXRX
| Q4 25 | $396.7M | $-47.3M | ||
| Q3 25 | $100.8M | $-117.6M | ||
| Q2 25 | $78.1M | $-79.6M | ||
| Q1 25 | $87.8M | $-133.8M | ||
| Q4 24 | $642.0M | $-116.7M | ||
| Q3 24 | $132.6M | $-63.8M | ||
| Q2 24 | $123.1M | $-83.4M | ||
| Q1 24 | $188.3M | $-109.0M |
自由现金流率NNIRXRX
| Q4 25 | 1183.0% | -133.1% | ||
| Q3 25 | 435.0% | -2272.5% | ||
| Q2 25 | 299.0% | -413.9% | ||
| Q1 25 | 355.6% | -907.4% | ||
| Q4 24 | 3438.0% | -2567.7% | ||
| Q3 24 | 797.9% | -244.6% | ||
| Q2 24 | 829.2% | -578.5% | ||
| Q1 24 | 1473.7% | -789.9% |
资本支出强度NNIRXRX
| Q4 25 | 78.2% | 3.5% | ||
| Q3 25 | 50.4% | 4.7% | ||
| Q2 25 | 14.2% | 16.4% | ||
| Q1 25 | 13.7% | 12.4% | ||
| Q4 24 | 111.9% | 28.6% | ||
| Q3 24 | 26.7% | 17.5% | ||
| Q2 24 | 71.5% | 8.2% | ||
| Q1 24 | 181.7% | 48.2% |
现金转化率NNIRXRX
| Q4 25 | 7.32× | — | ||
| Q3 25 | 1.05× | — | ||
| Q2 25 | 0.45× | — | ||
| Q1 25 | 1.10× | — | ||
| Q4 24 | 10.50× | — | ||
| Q3 24 | 57.39× | — | ||
| Q2 24 | 2.97× | — | ||
| Q1 24 | 2.88× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
